Frances Stocks Allen

  • 99 Bishopsgate
  • London EC2M 3XF
  • United Kingdom

Frances Stocks Allen is a life sciences associate in the firm's London office. Ms. Stocks Allen practices in the firm’s Corporate Department, focusing primarily on transactional, licensing, intellectual property, and regulatory matters.

Ms. Stocks Allen advises on a broad spectrum of licensing and other complex commercial and intellectual property arrangements including licensing, distribution, supply, and complex corporate separation and divestment in the life sciences sector. Ms. Stocks Allen also has expertise in EU and UK regulatory issues and data privacy, including the General Data Protection Regulation (GDPR).

In 2017, Ms. Stocks Allen was seconded to the firm's Silicon Valley office to work on cutting-edge biotechnology and licensing matters in the life sciences sector. In 2015, Ms. Stocks Allen was seconded in-house to Allergan, where she worked as part of the global commercial team, advising on licensing and other commercial arrangements, and assisting with the implementation of its US$66 billion acquisition by Actavis.

Ms. Stocks Allen is a Committee member of Women in Law London (WILL), an active professional network with approximately 2,000 members, promoting the advancement of women solicitors.

Ms. Stocks Allen's representative transactions include advising:

  • Allergan plc on all commercial, licensing, supply, quality, safety, separation, and transitional matters in connection with its US$40.5 billion divestment of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd
  • A women's health products provider on all pre-closing commercial, licensing, supply, quality, safety, separation, and transitional matters in connection with its acquisition of certain women’s health products from a leading pharamceutical company
  • Guardant Health in connection with its strategic joint venture with SoftBank, including negotiation of the joint venture, licensing, distribution, and assignment agreements
  • A leading genetic engineering company in the negotiation of a research and collaboration agreement with a research institute in respect of the research institute's proprietary technology for the development of gene and cellular therapies for the diagnosis, treatment, and prevention of diseases and conditions, including, but not limited to primary immunodeficiencies and auto-immune disease
  • A leading genetic engineering company in the negotiation of a research and collaboration agreement with a pharmaceutical company in respect of the pharmaceutical company's proprietary technology in the formulation, use, and manipulation of synthetic DNA
  • A clinical stage UK-based biopharmaceutical company focused on rare and specialty diseases on its exclusive license agreement with a multinational biopharmaceutical company for an oral inhibitor of neutrophil elastase
  • A specialty pharmaceutical company on the negotiation of an exclusive license agreement and exclusive supply agreement with a research and diagnostic development company for use of its proprietary cell isolation, detection, and analysis technology in the field of early cancer screening
  • A pharmaceutical corporation on the negotiation of a Co-Promotion Agreement with a US-based manufacturer of pharmaceutical products for an anaplastic lymphoma kinase (ALK) inhibitor product
  • A biotechnology company in connection with complex licensing and privacy compliance matters, including its exclusive in-licensing of assets from a Swiss multinational healthcare company
  • Meda AB on all commercial, regulatory, separation, and transitional arrangements in relation to its disposal of Euromed SA, a leading European manufacturer of herbal extracts and natural active substances, to The Riverside Company
  • Actavis on its divestment of part of its Western European generics sales and marketing business to Aurobindo  


Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.